Literature DB >> 22480734

Signal transduction pathway activity compensates dopamine D₂/D₃ receptor density changes in Parkinson's disease: a preliminary comparative human brain receptor autoradiography study with [³H]raclopride and [³⁵S]GTPγS.

Szabolcs Farkas1, Katalin Nagy, Zhisheng Jia, Tibor Hortobágyi, Andrea Varrone, Christer Halldin, László Csiba, Balázs Gulyás.   

Abstract

The degeneration of dopaminergic nigrostriatal pathway in Parkinson's disease (PD) results in alterations of the dopamine receptor system. In the present study we have investigated the relationship between the disease related changes of expressed dopamine D₂/D₃ receptor density and the corresponding intracellular signal transduction route in cortical and sub-cortical brain structures in the human brain. Dopamine D₂/D₃ receptor autoradiography (ARG), using [³H]raclopride, and agonist stimulated [³⁵S]GTPγS (guanosine 5'-O-[γ-thio]triphosphate) binding autoradiography have been performed in human striatum, cingulate gyrus and medial frontal gyrus samples obtained from six deceased PD patients and six age matched control subjects. Receptor densities were expressed as fmol/gram tissue protein for [³H]raclopride; agonist stimulated [³⁵S]GTPγS binding was expressed in fmol/gram tissue and its change was expressed in percentage values above basal binding. Our results indicate that whereas there is a decrease of the dopamine D₂/D₃ receptors in the striatum demonstrated by classical receptor autoradiography (controls and PD: 24.08±2.06 fmol/gram (mean±SEM) and 18.43±2.82 fmol/gram, respectively; p<0.05), the corresponding agonist stimulated [³⁵S]GTPγS binding autoradiography shows unchanged basal [³⁵S]GTPγS binding (controls and PD: 199±17 fmol/g and 198±21 fmol/g, respectively; n.s.) and, at the same time, no change in stimulation (controls and PD: 0.40±4.57% and 1.51±2.27%, respectively; n.s.). In cingular gyrus and medial frontal gyrus neither the dopamine D₂/D₃ receptor densities nor the [³⁵S]GTPγS binding displayed significant differences between PD and age matched control brain samples, whereas the [³⁵S]GTPγS binding values were markedly higher in PD. These preliminary findings may indicate a possible compensatory mechanism in striatal regions of PD brains: the loss of the dopamine receptors in the striatum appears to be compensated by an increased post-synaptic intracellular signal transduction route activity. However, the accurate interpretation of the present findings requires detailed further studies.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22480734     DOI: 10.1016/j.brainres.2012.03.014

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  NOX1/NADPH Oxidase Promotes Synaptic Facilitation Induced by Repeated D2 Receptor Stimulation: Involvement in Behavioral Repetition.

Authors:  Nozomi Asaoka; Masakazu Ibi; Hikari Hatakama; Koki Nagaoka; Kazumi Iwata; Misaki Matsumoto; Masato Katsuyama; Shuji Kaneko; Chihiro Yabe-Nishimura
Journal:  J Neurosci       Date:  2021-02-09       Impact factor: 6.167

2.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

3.  Influence of angiotensin-converting enzyme inhibition on reversibility of alterations in arterial wall and cognitive performance associated with early hypertension: A follow-up study.

Authors:  Enikő Csikai; Mónika Andrejkovics; Bernadett Balajthy-Hidegh; Gergely Hofgárt; László Kardos; Ágnes Diószegi; Róbert Rostás; Katalin Réka Czuriga-Kovács; Éva Csongrádi; László Csiba
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.